Promoted Content
Promoted Content

Find Novel Psychiatry/Psychology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            EmpathBio

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNC210,EMP-01

            Therapeutic Area: Psychiatry/Psychology Product Name: BNC210

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bionomics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 17, 2021

            Details:

            Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4 Methylenedioxymethamphetamine (MDMA) derivative EMP-01.

            MindShift Compounds

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 11, 2021

            Details:

            The partnership on these initial targets will expand MindMed’s current, well-established clinical pipeline with additional backup and expansion compounds with similar and potentially improved therapeutic properties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: OX124

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2021

            Details:

            The new patent is the second US patent for OX124. Based on Orexo's innovative scalable intranasal formulation technology, OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from synthetic opioids, such as fentanyl.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tryptamine derivatives

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Adelia Therapeutics

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 11, 2021

            Details:

            The achievement includes the successful synthesis of multiple tryptamine derivatives in sufficient quantities, drug ADME/PK has been completed and to demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAGE-319

            Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-319

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            As part of the presentation, Mr. Greene will highlight the Company’s planned portfolio expansion and acceleration in 2021, including the anticipated advancement of SAGE-718, SAGE-689 and SAGE-904 into further phases of development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Revive Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 21, 2020

            Details:

            The Acquisition follows the previously announced exclusive research collaboration agreement with PharmaTher to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ART26.12

            Therapeutic Area: Psychiatry/Psychology Product Name: ART26.12

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mitacs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding November 23, 2020

            Details:

            The grant is expected to fund 50% of expenses related to preclinical research investigating ART26.12 as a potential treatment for anxiety disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRL-4

            Therapeutic Area: Psychiatry/Psychology Product Name: NRL-4

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            NRL-4 is a proprietary formulation incorporating the science of Intravail®, which provides consistent and reliable absorption of medication via a proven, commercially available, single-use nasal sprayer.